NCT01811160COMPLETEDanonymous

Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics

Sponsor

Source record

Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente

Phase

Source record

Phase 4

Modality

AI-normalized

gene therapy

Target

AI-normalized

Metabolic disturbances associated with Second Generation Antipsychotics (SGA)

Indication / condition

AI-normalized

Second Generation Antipsychotic Induced Metabolic Adverse Effects

Intervention

Source record

Melatonin, Placebo

Source & freshness

Source record

NCT ID

NCT01811160

Original source

ClinicalTrials.gov

Source last updated

Mar 14, 2013

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01811160

Title

Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics

Sponsor

Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente

Status

COMPLETED

Phase

Phase 4

Condition raw

Second Generation Antipsychotic Induced Metabolic Adverse Effects

Condition normalized

Second Generation Antipsychotic Induced Metabolic Adverse Effects

Modality raw

Second Generation Antipsychotic Induced Metabolic Adverse Effects

Modality normalized

gene therapy

Target raw

Metabolic disturbances associated with Second Generation Antipsychotics (SGA)

Target normalized

Metabolic disturbances associated with Second Generation Antipsychotics (SGA)

Interventions

Melatonin, Placebo

Public preview

Source record

This clinical trial investigated the effects of melatonin on metabolic side effects in patients treated with second generation antipsychotics for schizophrenia or bipolar disorder. The study aimed to address the significant metabolic risks associated with SGA, which include weight gain and dysregulation of glucose and lipids.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01811160

Status

COMPLETED

Phase

Phase 4

Sponsor

Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMar 14, 2013

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01811160

Indication

Second Generation Antipsychotic Induced Metabolic Adverse Effects

Modality

gene therapy

Target

Metabolic disturbances associated with Second Generation Antipsychotics (SGA)

Intervention

Melatonin, Placebo

Source record